CLLS - セレクティス (Cellectis S.A.) セレクティス



symbol CLLS
会社名 Cellectis SA (セレクティス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS) used for gene excision correction or replacement. The Company also offers rational inverse genetics and targeting recombination tools. Cellectis SA markets its technologies mainly for use in the research field in pharmaceutical drug discovery programs in the agronomics bioproduction and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States among others.   セレクティスは、フランスのゲノム工学会社。独自のコア技術を採用し、免疫腫瘍学の分野で製品を開発する。同社の製品には、B細胞悪性腫瘍などのCD19を有する細胞を標的とし殺傷することのできるT細胞製品のUCART19がある。また、製品の候補には、UCART123、UCARTCS1、UCART38などがある。   
本社所在地 8 rue de la Croix Jarry Paris 75013 FRA
代表者氏名 Andre Choulika アンドレ・チュリカ
代表者役職名 Chairman of the Board Chief Executive Officer Member of the Executive Board
電話番号 +33 1-8169-1600
設立年月日 36526
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 135人
adr_tso 16101659
EBITDA EBITDA(百万ドル) -99.62027
終値(lastsale) 27.45
時価総額(marketcap) 441990539.55
時価総額 時価総額(百万ドル) 1121.578
売上高 売上高(百万ドル) 30.85860
企業価値(EV) 企業価値(EV)(百万ドル) 631.49400
当期純利益 当期純利益(百万ドル) -85.63750
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Cellectis SA (ADR) revenues decreased 15% to $16.4M. Net loss decreased 30% to $32.4M. Revenues reflect Revenues decrease of 16% to $11.1M Other income decrease of 12% to $5.3M. Lower net loss reflects Financial expenses decrease of 74% to $3M (expense) Financial Income increase from $4.7M to $13M (income) Research and development expenses decrease of 5% to $36.4M (expense).



   TCR-based Therapies Market Skyrocketing $4 Bn by 2028| Autolus, bluebird bio, CARsgen Therapeutics, Celgene, Cell Medica, Cellectis, Cellular Biomedicine Group, Immunocore, Innovative Cellular Therapeutics, Kite Pharma, Lion TCR, ZIOPHARM Oncology  2021/09/10 11:19:27 OpenPR
TCR-based Therapies Market is projected to reach at $4 Bn at a CAGR +13% by the time lapse of 2021-28. TCR-based Therapies involves treating cancer with activated T lymphocytes from the body. Both strategies attach new receptors to the cells'' surfaces,
   Cellectis Announces Participation in Five Investor Conferences  2021/08/26 20:34:00 Intrado Digital Media
NEW YORK, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS EURONEXT GROWTH: ALCLS) (the Company), a gene-editing platform company with clinical-stage immuno-oncology programs using allogeneic chimeric antigen receptor (CAR)-T cells and gene therapy programs for monogenic diseases, today announced that management plans to participate in five virtual investor conferences.
   T-Cell Immunotherapy Market Set for Rapid Growth and Trend by 2021-2027 | Cellectis, Takara Bio  2021/08/18 07:47:15 OpenPR
This informative T-Cell Immunotherapy market report covers small bunch of information for a scope of period including from 2021 to 2027. This figure ends up being exceptionally gainful for the forthcoming business sector business people. This information in a factual
   Cellectis S.A. (CLLS) CEO André Choulika on Q2 2021 Results - Earnings Call Transcript  2021/08/06 19:33:04 Seeking Alpha
   Cellectis Provides Business Update and Reports Financial Results for Second Quarter and First Six Months 2021  2021/08/05 20:30:00 Intrado Digital Media
Preliminary translational data validate UCARTCS1 as a promising potential therapy for relapsed or refractory multiple myeloma patients.
   The Daily Biotech Pulse: Lilly, Morphic''s Positive Data At ECCO, Humanigen''s COVID Treatment Gets Expedited Review In UK, TransCode IPO  2021/07/09 11:36:16 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8) Aerpio Pharmaceuticals, Inc. (NASDAQ: ARPO ) ( moved on positive analyst action) Ambrx Biopharma Inc. (NYSE: AMAM ) AtriCure, Inc. (NASDAQ: ATRC ) Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN ) BioLife Solutions, Inc. (NASDAQ: BLFS ) Edwards Lifesciences Corporation (NYSE: EW ) Novo Nordisk A/S (NYSE: NVO ) Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX ) West Pharmaceutical Services, Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 8) 89bio, Inc. (NASDAQ: ETNB ) AbCellera Biologics Inc. (NASDAQ: ABCL ) Achilles Therapeutics plc (NASDAQ: ACHL ) Adicet Bio, Inc. (NASDAQ: ACET ) ADMA Biologics, Inc. (NASDAQ: ADMA ) Aerovate Therapeutics, Inc. (NASDAQ: AVTE ) (IPOed June 30) Agile Therapeutics, Inc. (NASDAQ: AGRX ) Akero Therapeutics, Inc. (NASDAQ: AKRO ) (announced positive Phase 2 data for non-alcoholic steatohepatitis drug) Allogene Therapeutics, Inc.
   Professional Study Report On Global Chimeric Antigen Receptor (CAR)-T Therapy Treatment Market Potential Rate Period Of 32.00% Of 2021 To 2028||Bristol-Myers Squibb Company, CARINA BIOTECH, CARsgen Therapeutics, Cartherics Pty ltd, Cellectis, Ziopharm Onc  2021/07/06 09:31:48 OpenPR
Chimeric Antigen Receptor (CAR)-T Therapy Treatment Market 2021 provides the most up-to-date market insight and analysis. The key players of the market are making moves like product launches, joint ventures, developments, mergers, and acquisitions which is affecting the market
   Global CAR-T Therapy Treatment Market Overview, Industry Top Manufactures, Size, Growth rate 2021 -2028||BioAtla LLC. , bluebird bio, Inc, CELGENE CORPORATION, CARINA BIOTECH, CARsgen Therapeutics, Cartherics Pty ltd, Cellectis, Ziopharm Oncology  2021/07/05 07:37:04 OpenPR
Global CAR-T Therapy Treatment Market is a professional and exhaustive report which focuses on primary and secondary drivers, market share, leading segments and geographical analysis. This market research report contains fundamental, secondary and advanced information related to the global status
   CRISPR: 4 Emerging Players  2021/06/30 13:06:12 Seeking Alpha
   Cellectis: FYE 2021 TALEN CAR-T Data Announcement Should Catalyse Strong Upside  2021/06/22 17:00:00 Seeking Alpha
   Cellectis: FYE 2021 TALEN CAR-T Data Announcement Should Catalyse Strong Upside  2021/06/22 17:00:00 Seeking Alpha
   Cellectis outlines four new UCART preclinical programs; reveals .HEAL, a genome surgery platform  2021/06/15 07:16:25 Seeking Alpha
   Cellectis'' Innovation Days event highlighted New Product Development, New Genome Surgery Platform .HEAL, and Manufacturing Capabilities  2021/06/14 20:30:00 Benzinga
Four new product candidates under pre-clinical development announced; UCART20x22; the first allogeneic bi-specific CAR-T cell targeting B-cell malignancies, and three additional product candidates for solid tumors UCARTMESO (targeting Mesothelin), UCARTMUC1 (targeting Mucin 1), UCARTFAP (targeting Cancer Associated Fibroblasts) .HEAL, Cellectis'' proprietary genome surgery HSC platform announced; initiating the Company''s venture into new disease targets; Sickle Cell Anemia, Lysosomal storage disease (LSD) and Primary Immunodeficiencies Cellectis'' GMP manufacturing facilities showcase new capabilities including; building more independence from contract manufacturing organizations and gain an increased control over gene and cell therapy process and development Proprietary integrated gene editing suite with Cellectis'' electroporation device PulseAgile and GeneEngine ; expanding its electroporation capabilities NEW YORK, June 14, 2021 (GLOBE NEWSWIRE) -- Cellectis S.A. (NASDAQ: CLLS ) (the "Company"), a clinical-stage biotechnological company employing its core proprietary technologies to develop products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor (CAR) T-cells in the field of immuno-oncology and gene-edited hematopoietic stem cells ("HSC") in other therapeutic indications, featured the Cellectis Innovation Days , a company event held on May 24-28, virtually.
   Gecina Pre-lets the Biopark Building in Paris 13th Arrondissement  2021/06/09 16:25:00 Business Wire
PARIS--(BUSINESS WIRE)--Regulatory News: Gecina (Paris:GFC) is delighted to welcome a group of leading biotechnology, digital and health companies to its Biopark building located in Paris 13th arrondissement. The firm nine-year lease covers all of the space in Building E, representing around 6,400 sq.m, which will be available to the tenant from September 1, 2021. With the existing tenants Cellectis and Parexel International, the Biopark real estate complex is a specialist life sciences hub. C
   Cellectis SA Stock Gives Every Indication Of Being Possible Value Trap  2021/06/05 05:01:33 GuruFocus
Related Stocks: CLLS ,

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 セレクティス CLLS Cellectis S.A.)

 twitter  (公式ツイッターやCEOツイッターなど)